Natural peptides versus COVID-19
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
List view / Grid view
Peptides could serve as a potential platform for development of novel drugs for the treatment of the COVID-19 coronavirus.
Histone deacetylase 2 (HDAC2) plays a key role in the regulation of inflammatory response in monocytes so could be a target for COVID-19, argue Dr Rosa Maria Tordera and Maria Cortes.
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Researchers have found a lead compound which they say inhibits SARS-CoV-2 viral replication and demonstrates good pharmacokinetic activity in vivo.
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
A new study has revealed that less than 10 percent of respiratory and intestinal cells are susceptible to SARS-CoV-2 infection and expression of ACE2 receptors is driven by the body's immune response.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
Researchers in the UK have selected nanobodies that bind with high affinity to the Spike protein on the COVID-19 coronavirus, enabling stabilisation for imaging.
An international consortium suggest that the severe symptoms of COVID-19, including Acute Respiratory Distress Syndrome (ARDS), could be caused by Neutrophil Extracellular Traps (NETs).
How has evolution led us to the point where humans are an ideal host for SARS-CoV-2, the virus that causes the COVID-19 coronavirus?
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
Researchers working on related coronaviruses SARS and MERS have identified the membrane fusion peptide on the Spike protein as a possible drug target for SARS-CoV-2, the virus causing COVID-19.
Sequencing almost 60,000 cells, researchers have found that certain cilia progenitor cells have gene transcripts for ACE2 and co-factor TMPRSS2, enabling COVID-19 infection.
The interaction between a SARS antibody called CR3022 and the COVID-19 coronavirus has been mapped by researchers, revealing a viral vulnerability.